Efficacy and safety of epicutaneous immunotherapy for severe egg allergy; Long term trial

Phase 2

• Conditions: Food allergy

• Registration Number: JPRN-UMIN000025381
• Lead Sponsor: ational Hospital Organization Mie National Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-12-23
• Study Completion: 2018-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) Allergy to soy and milk 2) Large change in intake levels of egg before 3 months of the trial 3) Complication or past history of heart, liver and kidney diseases 4) Uncontrolled asthma or atopic dermatitis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of dose threshold in oral egg challenge from 24 weeks to 48 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
1.Change of dose threshold in oral egg challenge after 24 weeks of treatment 2.Safety:local reaction,systemic immediate-type allergic reaction and other 3.Prick test 4.Specific IgE and IgG4 5.Basophil activation test